Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
Protocol ID
PRN1008-018
Disease (Sub Disease)
Immune Thrombocytopenia
Diagnosis Stage
Recurrent/ refractory
Sponsor
Principia Biopharma, a Sanofi Company
Links
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 3
Age Eligibility
12 Years and older
International registry ID's
NCT04562766
| Study Title | Ph3 Randomized Double-Blind Placebo-Controlled Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) |
|---|---|
| Protocol ID | PRN1008-018 |
| Disease (Sub Disease) | Immune Thrombocytopenia |
| Diagnosis Stage | Recurrent/ refractory |
| Sponsor | Principia Biopharma, a Sanofi Company |
| Links | https://clinicaltrials.gov/ct2/show/NCT04562766 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 14/12/2020 |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | 12 Years and older |
| International registry ID's | NCT04562766 |